Browse the evidence

Cholecystokinin (CCK) attenuates reward-related signaling and motivation for food, acting as a satiety signal that can block the acquisition of conditioned place preference associated with rewarding stimuli.

Satiety hormones like CCK don't just turn off hunger; they can also reduce the reward value of food, making it less appealing.

GLP-1 receptor agonists should be discontinued prior to metabolic bariatric surgery to prevent delayed gastric emptying and aspiration pneumonia during anesthesia.

If you take GLP-1 medications (like Ozempic or Saxenda) and are having bariatric surgery, you MUST stop them before the procedure. Daily users should stop on the day of surgery; weekly users should stop one week prior. This prevents life-threatening aspiration pneumonia.

Strict glycemic control is the only intervention proven to prevent or delay the development of diabetic neuropathy in patients with type 2 diabetes.

If you have Type 2 Diabetes, keeping your blood sugar strictly under control is the most important thing you can do to prevent nerve damage (neuropathy). While other drugs and lifestyle changes are used, strict glucose management is the only proven way to stop or slow this specific complication. Regular foot checks and patient education are also critical to catch issues early.

Saturated fats do not cause cardiovascular disease; instead, coronary heart disease is driven by silent inflammation resulting from insufficient omega-3s, excessive omega-6s, and high fructose intake.

Stop fearing natural saturated fats like those in butter and meat. Instead, focus on reducing processed foods, sugar (especially fructose), and industrial trans fats. Ensure you get enough omega-3s from fish or supplements to manage inflammation, as this is the true driver of heart disease, not the saturated fat itself.

Palmitic acid is only harmful when produced endogenously via de novo lipogenesis from excess fructose; dietary palmitic acid is not the primary culprit for metabolic issues.

You don't need to strictly avoid dietary palmitic acid (found in meat, butter, palm oil). The real danger is consuming too much fructose (sugar, juice), which your liver converts into palmitic acid, causing inflammation. Reduce sugar, and your body handles saturated fats much better.

GLP-1 receptor agonists (GLP-1RAs) exert immunoregulatory effects by promoting the polarization of macrophages and microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, thereby reducing neuroinflammation and systemic inflammatory markers.

If you are using a GLP-1RA (like semaglutide or liraglutide) for diabetes or weight loss, understand that it may also be helping to lower systemic inflammation by shifting your immune cells toward a less inflammatory state. This is not just a side effect but a direct mechanism of action on your immune system.

GLP-1RAs modulate T cell differentiation by reducing the proportion of pro-inflammatory Th17 cells and increasing regulatory T cells (Tregs), thereby improving immune tolerance and reducing inflammation in conditions like psoriasis and colitis.

For those with autoimmune conditions, GLP-1RAs may help rebalance your immune system by reducing inflammatory T cells and boosting regulatory ones. This could potentially complement standard treatments by addressing the underlying immune imbalance.

GLP-1RAs reduce innate allergic inflammation and eosinophilia by inhibiting the activity of Group 2 Innate Lymphoid Cells (ILC2s) and reducing the production of type 2 cytokines (IL-5, IL-13).

If you have allergic asthma, GLP-1RAs might help reduce the specific allergic inflammation driven by innate immune cells, potentially easing symptoms beyond just metabolic benefits.

GDF15, a member of the TGF-β superfamily, acts as a central regulator of appetite and a potential treatment for obesity by reducing food intake and stimulating lipolysis.

GDF15 is a hormone that reduces food intake and increases fat burning. Research suggests it could be a future treatment for obesity, offering a different mechanism from current drugs.

Adiposity causes coronary heart disease (CHD), although the causal effect size is smaller and less statistically robust than for heart failure or stroke in this specific analysis.

Managing your weight can help reduce your risk of coronary heart disease. While the link might be less direct than for heart failure, reducing adiposity can lower the risk of atherosclerosis and related heart issues. Consult with a healthcare provider for personalized advice.

GLP-1-based therapies and SGLT2 inhibitors provide protective effects on the coronary microvascular compartment in diabetic patients, addressing coronary microvascular dysfunction (CMD).

If you have diabetes and signs of heart issues like chest pain or shortnessess of breath without blocked arteries (CMD), ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs are increasingly recognized to protect the small blood vessels in the heart, beyond just lowering blood sugar.

Long-term LCHF diet adaptation may lead to the early development of central fatigue during exercise due to elevated blood concentrations of non-esterified fatty acids (NEFA) and ammonia.

Be aware that switching to a low-carb diet might make you feel mentally tired or 'lethargic' during exercise, especially early on. This is due to changes in blood chemistry (fatty acids and ammonia) affecting your brain. This is a known potential downside of LCHF that may counteract physical benefits.

Endogenous GLP-1 secretion is stimulated by specific nutrient-sensing mechanisms in intestinal L-cells, including SGLT1 and KATP channels for carbohydrates, FFA1 and GPR119 for fats, and Pept1 and CaSR for proteins.

This paper explains the biological 'sensors' in your gut that trigger GLP-1 release when you eat carbs, fats, and proteins. While understanding these mechanisms (like SGLT1 for sugar or GPR119 for fat) is crucial for drug development, there are currently no standard dietary protocols to specifically target these receptors for therapeutic GLP-1 elevation. The paper highlights that while animal models show clear results, human applicability is still being researched.

Long-term adherence to GLP-1 receptor agonist therapy significantly reduces the risk of major adverse liver outcomes (MALO) in patients with chronic liver disease and type 2 diabetes, whereas intention-to-treat analysis shows no significant benefit due to high discontinuation rates.

If you have chronic liver disease and type 2 diabetes, GLP-1 medications (like semaglutide or liraglutide) can significantly lower your risk of serious liver complications (like cirrhosis or liver cancer) over 10 years, BUT only if you keep taking them. Half of the patients in this study stopped taking the drug, which erased the benefit in the general group. To get the liver protection, you must manage side effects and stay on the treatment long-term.

Obesity is associated with altered nutrient sensing mechanisms in the gut, specifically region-dependent changes in the expression of amino acid and bitter taste receptors, which may contribute to inconsistent gut hormone fluctuations.

In obesity, the gut's ability to sense nutrients like proteins and fats changes depending on the location in the gut. This altered sensing contributes to why hormone signals (like GLP-1 or PYY) might not work as expected in obese individuals compared to lean ones.

Individuals who are lean and metabolically healthy (low BMI, low triglycerides, high HDL) experience marked elevations in LDL cholesterol when consuming a carbohydrate-restricted diet, a phenotype termed 'lean mass hyper-responder' (LMHR).

If you are lean and metabolically healthy, a low-carb diet might significantly raise your LDL cholesterol. This does not necessarily mean your heart health is worse, as your other markers (triglycerides, HDL) are likely excellent. If you are concerned, you can moderately increase carbohydrate intake (50-100g/day) to lower LDL, or continue the diet while monitoring other risk factors. Consult a doctor to interpret your full lipid profile in context.

Elevated serum Interleukin-6 (IL-6) levels in sarcopenic obesity drive insulin resistance and muscle protein degradation through NF-kB and FOXO/Smad pathways.

High inflammation (IL-6) is not just a marker but a driver of muscle loss and blood sugar issues in sarcopenic obesity. Reducing inflammation may be key to preserving muscle and metabolic health in this population.

Semaglutide is associated with a significantly higher reporting odds ratio for gastrointestinal adverse drug reactions (GADRs) compared to liraglutide, with a later median time-to-onset (7 days vs 4 days).

If you are considering GLP-1 weight loss drugs, know that semaglutide is associated with a higher reporting rate of stomach issues (nausea, vomiting, etc.) and a later onset of these symptoms compared to liraglutide. To minimize side effects, insist on a slow dose titration starting at the lowest dose. If semaglutide causes intolerable side effects, discuss switching to liraglutide, which may have a different gastrointestinal risk profile.

A single subcutaneous injection of a biomimetic hydrogel depot containing GLP-1 receptor agonists (semaglutide or liraglutide) sustains therapeutic drug exposure for approximately 42 days in rats, enabling a once-every-4-months dosing regimen in humans that maintains blood glucose and weight management comparable to daily or weekly injections.

This research suggests that a new type of injection using a hydrogel depot could allow people with type 2 diabetes to take their GLP-1 medication (like semaglutide or liraglutide) only once every four months instead of daily or weekly. In animal studies, this single shot kept blood sugar and weight under control just as well as taking the drug every day. While the technology is promising, it is currently only proven in rats, so human dosing and safety are not yet confirmed.

In lean individuals with low baseline triglycerides, carbohydrate-restricted diets cause elevated LDL-C and HDL-C through increased hepatic VLDL secretion and lipoprotein lipase (LPL)-mediated turnover, rather than through atherogenic dyslipidemia mechanisms.

If you are lean and keep your triglycerides low while eating low-carb, your LDL might rise significantly. This paper suggests this is likely due to efficient fat burning (high LPL activity) rather than the dangerous type of high cholesterol seen in obesity/diabetes. Monitor your triglycerides and HDL; if TG is low and HDL is high, the high LDL may be less concerning, though long-term cardiovascular outcomes in this specific group require more research.

Acute moderate-intensity aerobic exercise has no significant effect on plasma levels of obestatin or des-acyl ghrelin in overweight women.

Don't expect moderate running to change your levels of obestatin or des-acyl ghrelin. These specific hormones remain stable during and after a 60-minute moderate run in overweight women. Focus on the changes in acyl ghrelin and leptin instead.

GLP-1 receptor agonists (GLP-1RAs) activate brown adipose tissue (BAT) in humans, increasing its metabolic volume and glucose uptake, although this activation does not necessarily translate to increased fat fraction reduction or resting energy expenditure in all clinical contexts.

If you are using a GLP-1 medication like semaglutide or liraglutide, part of its benefit comes from activating your brown fat, which burns energy as heat. This happens alongside reduced appetite. While this doesn't always show up as 'less fat' in immediate scans, it contributes to better metabolic health and weight management. Stick with the treatment as prescribed.

Type 2 diabetes mellitus impairs weight reduction in obese patients primarily through energy conservation (reduced glucosuria), hyperinsulinemia-driven lipid storage, and the use of obesogenic anti-diabetes medications.

If you have Type 2 Diabetes and struggle to lose weight, it is likely not just a willpower issue. Your body is conserving energy because your blood sugar is better controlled (less sugar peed out), and medications like insulin or sulfonylureas may be actively promoting fat storage. Discuss switching to diabetes medications that support weight loss (such as GLP-1 agonists or SGLT2 inhibitors) with your doctor, as these can help overcome these physiological barriers.

Obesogenic anti-diabetes medications, specifically those that increase insulin exposure (insulin, sulfonylureas, meglitinides), actively promote weight gain and hypoglycemia, which necessitates increased caloric intake and impairs weight loss.

If you are taking insulin, sulfonylureas, or meglitinides, these drugs may be making weight loss impossible by causing low blood sugar (hypoglycemia). To prevent lows, you may be eating extra carbs. Ask your doctor about switching to diabetes medications that do not cause hypoglycemia or weight gain, such as GLP-1 agonists or SGLT2 inhibitors.